Clinical research of targeted drug combined with chemotherapy for primary central nervous system lymphoma
10.3760/cma.j.issn.1671-8925.2014.01.000
- VernacularTitle:靶向联合化疗治疗原发性中枢神经系统淋巴瘤的研究
- Author:
Baoshi CHEN
1
;
Zhiyong BI
;
Zhong ZHANG
;
Fusheng LIU
Author Information
1. 首都医科大学附属北京天坛医院神经外科
- Keywords:
Rituximab;
High-dose methotrexate;
Primary central nervous system lymphoma;
Targeted therapy
- From:
Chinese Journal of Neuromedicine
2014;13(1):83-85
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of new therapy of high-dose methotrexate (HD-MTX,3 g/m2) combined with rituximab on primary central nervous system lymphoma.Methods Thirty-seven patients with primary central nervous system lymphoma,admitted to our hospital from January 2006 to January 2013,were chosen in our study; targeted therapy group (n=9) accepted chemotherapy scheme (HD-MTX +Rituximab 375 mg/m2) for 2-6 cycles (4 weeks a cycle),and the traditional treatment group adopted whole brain radiotherapy plus HD-MTX for 2-6 cycles.Progressive free survival (PFS) was compared between the two groups.Results Complete response was achieved in 5 patients of targeted therapy group,partial response in 2,stable disease in 1 and progressive disease in 1.Complete response was achieved in 12 patients of traditional treatment group,partial response in 11,stable disease in 4 and progressive disease in 2.The median PFS in the targeted therapy group was 28 months while that in the traditional treatment group was 11 months,with significant difference (R=0.823,P=0.021).Conclusion The scheme of HD-MTX combined with Rituximab for primary central nervous system lymphoma relieves the side-effect of the traditional therapy and gains satisfied results,which can be recommended as an effective therapy for primary central nervous system lymphoma.
